---
title: "Type 1 Diabetes Care: Hypoglycemia Burden and Beta-Cell Replacement Research"
id: "endocrine-news-0-type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care/"
published_at: "2026-11-20T14:16:44.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Type 1 Diabetes Care: Hypoglycemia Burden and Beta-Cell Replacement Research
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care/)
- **Published At:** 2026-11-20T14:16:44.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- **Type 1 diabetes** is an autoimmune disease caused by permanent destruction of insulin-producing beta cells; adults now constitute the majority of cases and the median age at diagnosis is 24 years. - Historical advances—from insulin discovery to continuous glucose monitoring (CGM) and automated insulin delivery (AID)—have improved survival but not removed daily management burdens. - Around 2.1 million people in the U.S. live with type 1 diabetes and require lifelong insulin therapy and ongoing glucose monitoring. - Insulin has a narrow therapeutic index; both insufficient and excess insulin carry acute risks: hypoglycemia can cause seizure, unconsciousness, or death, while hyperglycemia increases risk for diabetic ketoacidosis and long-term complications. - Investigators reported persistent elevated rates of long-term complications (retinopathy, cardiovascular disease, reduced life expectancy) even in patients who achieve glycemic targets. - Severe **hypoglycemia** is clinically defined by altered mental/physical function requiring assistance; many events are underreported because they occur at home and patients may not disclose them. - Clinical data cited: in a retrospective study of adults using advanced technologies, roughly 43% did not reach HbA1c <7%; about 20% reported ≥1 severe low and ~12% reported ≥2 severe lows in the prior year. - Impaired awareness of hypoglycemia (IAH) increases risk of severe events; having a recent low raises near-term recurrence risk substantially. - ICD-10 codes updated in October 2024 categorize hypoglycemia levels 1–3; level 3 (E16.A3) corresponds to severe events requiring third-party assistance regardless of glucose value. - Current beta cell replacement options: deceased donor islet transplantation and whole pancreas transplantation; both can restore insulin production but require lifelong immunosuppression and face access limitations. - Deceased donor islet transplantation outcomes have included near-normoglycemia and elimination of severe hypoglycemia in published reports, often requiring two to three infusions; donor scarcity and variable islet quality limit broader application. - Emerging manufactured islet cell therapies and next-generation closed-loop technologies are under investigation; the article notes research activity but does not report specific trial results or timelines. - Key unresolved issues documented: donor availability, need for immunosuppression, variability in cell quality, limited access despite FDA approval for some patients, and an absence of published methodology or outcome details for many investigational approaches.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/november-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/type-1-diabetes-setting-the-scene-and-the-evolution-of-type-1-diabetes-care/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Type 1 Diabetes: Setting the Scene and the Evolution of Type 1 Diabetes Care SPONSORED CONTENT BY VERTEX PHARMACEUTICALS By Tina Gupta, MD November 20, 2026 Print this article Share this article ![](https://endocrinenews.endocrine.org/wp-content/uploads/vertexlogoR_rgb-1-scaled.jpg) ##### Type1 diabetes care has advanced from insulin discovery to continuous glucose monitoring and automated insulin delivery, yet people living with the disease still face lifelong treatment demands, serious risks, and persistent unmet needs. Endocrine Society member Tina Gupta, MD, reviews these burdens alongside existing and emerging approaches to restore insulin-producing beta-cell function. **SPONSORED CONTENT BY VERTEX PHARMACEUTICALS** ![](https://endocrinenews.endocrine.org/wp-content/uploads/vertex_gupta.jpg) **_Tina Gupta, MD_** Type 1 diabetes is a chronic autoimmune disease caused by the permanent destruction of insulin-producing beta cells. Once perceived as a childhood disease, the reality today is that the majority of people living with type 1 diabetes are adults and the median age of diagnosis is 24 years old. The history of type 1 diabetes care is one of remarkable progress. The discovery of insulin in 1921 transformed type 1 diabetes from a fatal diagnosis into a chronic disease and care has since evolved dramatically — from porcine insulin and urine glucose testing to fast-acting insulins, continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems. While these technological advances have been life-changing for many, people living with type 1 diabetes still endure the burden of daily disease management, and unmet needs persist. The 2.1 million people living with type 1 diabetes in the U.S. require lifelong insulin therapy and constant glucose monitoring. Insulin is a lifesaving drug, but it has anarrow therapeutic index, and both insufficient and excess insulin can result in clinically significant consequences. As a result, individuals with type 1 diabetes face the daily challenge of glycemic management, potentially leading to episodes of hypoglycemia — which can cause seizures, unconsciousness, or death — and hyperglycemia, which increases the risk of diabetic ketoacidosis and long-term complications such as kidney failure and neuropathy. > While meaningful progress continues to be made, significant unmet needs remain. There is still more work to be done. It is critical that our work be guided by the lived experiences of people with type 1 diabetes and their caregivers. As we continue to move forward in science and discovery, I am excited to see how we may continue towards bringing meaningful progress to those living with this disease. Even among those who achieve target glucose levels, the risk of long-term complications remains elevated. Studies show increased rates of retinopathy, cardiovascular disease, and all cause mortality in people with type 1 diabetes compared to the general population — even when glycemic targets are met. One in four people with type 1 diabetes will progress to end-stage kidney disease and one in two people show signs of diabetic retinopathy after 30 years. Additionally, while people with type 1 diabetes are living longer, the disease is still associated with a reduction in life expectancy of greater than 10 years compared with the general population. The burden of type 1 diabetes is further compounded by the emotional and logistical challenges of 24/7 management, making type 1 diabetes not just a medical condition but a relentless daily challenge. ## **The Persistent Burden of Hypoglycemia** When I worked in clinic treating people with type 1 diabetes, hypoglycemia was one of the most feared complications of treatment for my patients and for me as their provider. That fear of low blood sugar can encourage cautious, and potentially insufficient, insulin dosing, resulting in chronic hyperglycemia and may lead to increased risk of long-term complications. I recall one patient, a surgeon, who would purposely run high while performing surgery to avoid a potential hypoglycemic event while in the operating room. Managing such a dangerous balancing act places not only a physical burden on the person with type 1 diabetes, but a psychological and social one as well. People experience hypoglycemia differently both in terms of symptoms and the speed at which their blood sugar drops. Some people may have clear warning signs, with common symptoms such as shakiness and confusion, while others suffer from impaired awareness of hypoglycemia (IAH), and are unaware of when their blood sugar drops, increasing the risk of severe hypoglycemic events. In the past, while working in the clinic, I would often grade the severity of a hypoglycemic event based on different characteristics: the glucose level, presence of clinical symptoms such as seizure or syncope, or degree of assistance needed, including use of glucagon or emergency medical services. However, clinical diabetes guidelines provide a clear definition for severe hypoglycemic events. These events are characterized by altered mental and/or physical functioning and require assistance from another person for recovery, irrespective of glucose level. Thinking back to my clinical practice, I realize that even when asking my patients about their lows, what constituted a severe hypoglycemic event to me may not have matched how my patients thought of it. As clinicians, it’s important to take the time to clearly define terms like severe hypoglycemic events to better recognize how often they occur and understand our patients’ experience with these dangerous events. ![](https://endocrinenews.endocrine.org/wp-content/uploads/Vertex_bldg-1024x573.jpg) _**The Jeffrey Leiden Center for Biologics, Cell & Genetic Therapies is comprised of two buildings dedicated to bring transformative therapies using cutting-edge genetic and cell-based technologies.**_ The notion that advances in technology have eliminated severe lows in people living with type 1 diabetes is not accurate. Further, even for those utilizing the latest technology, individuals with type 1 diabetes are often unable to achieve glycemic targets. In a retrospective, observational study by Jennifer Sherr, MD, PhD, et al., of 2,044 adults with type 1 diabetes, roughly 43% were not meeting the recommended HbA1c target of Pancreas transplantation and deceased donor islet cell transplantation are existing treatment options for select individuals with type 1 diabetes who experience severe hypoglycemia despite optimized glycemic management. However, these approaches have limitations including limited donor pancreas availability, variability in islet cell quality, and potential need for multiple infusions. Deceased donor islet recipients require daily immunosuppression medications to prevent rejection of the cells. While the FDA has approved this therapy for certain individuals with type 1 diabetes, access remains limited due to donor scarcity and quality. ## **Pancreas Transplantation** Whole pancreas transplantation is another option typically reserved for individuals with type 1 diabetes who are also undergoing kidney transplantation or who have significant challenges managing glucose levels and severe hypoglycemia. This surgical procedure can restore insulin production and potentially eliminate exogenous insulin. As with any organ transplant, lifelong immunosuppression is required so the body does not recognize the new organ as foreign and attack it. ## **Emerging Approaches: Research in Manufactured Islet Cell Therapies** The type 1 diabetes ecosystem continues to evolve. There is ongoing research focused on disease-modifying therapies to prevent or delay the onset of type 1 diabetes. Next-generation technologies such as fully closed-loop systems, manufactured islet cells, and personalized digital health tools are being investigated for their potential to address different aspects of type 1 diabetes management and unmet needs among people living with type 1 diabetes. As mentioned, pancreas transplantation and deceased donor islet cell transplantation are existing treatment options for select individuals with type 1 diabetes who experience severe hypoglycemia despite optimized glycemic management. However, these approaches have limitations including limite
## Related Clinical Research

- [MiniMed 780G Performance in Asian Adults With Type 1 Diabetes: 24-Week Exploratory Study](https://medichelpline.com/clinical-feed/pubmed-43056643.md) (DOI: 10.2196/94885)
- [WHO issues first guidelines on adult type 1 diabetes care](https://medichelpline.com/clinical-feed/who-0-0-who-issues-first-guidelines-on-type-1-diabetes-for-adults.md)
- [Diabetic ketoacidosis admissions fell 6.9% annually in a 10-year Norwegian cohort](https://medichelpline.com/clinical-feed/plos-one-18-trends-and-outcomes-in-diabetic-ketoacidosis-a-10-year-retrospective-study-at-a.md)
- [Diabetes After Solid-Organ Transplant: Multi‑Organ Registry Findings from ENDO 2026](https://medichelpline.com/clinical-feed/endocrine-news-0-looking-across-the-organs-diabetes-after-transplant.md)
- [Preconception, Gestational, and Postpartum Care for Type 2 Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-preconception-gestational-and-postpartum-care.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.